![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CARDIOME PHARMA TO BUY PRIVATELY HELD U.S FIRM ARTESIAN THERAPEUTICS FOR US$32M
CARDIOME PHARMA TO BUY PRIVATELY HELD U.S FIRM ARTESIAN THERAPEUTICS FOR US$32M
August 30, 2005
Cardiome Pharma Corp. has agreed to buy Artesian Therapeutics Inc., a privately held U.S. biopharmaceutical company, for a total of $32 million US. Gaithersburg, Md.-based Artesian researches and develops bi-functional small-molecule drugs for the treatment of cardiovascular disease. Under the terms of the proposed deal, payments to Artesian shareholders are contingent on the company meeting pre-defined clinical milestones totalling $32 million for the first two drug candidates from the Artesian programs that reach approval.
Canada.com (http://www.canada.com/health/story.html?id=500a1dd7-50f0-4310-b218-bb8f97717d05)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct